20th Anniversary of the Advances in Inflammatory Bowel Diseases conference (AIBD 2021)

Bathroom urgency could well predict UC severity

Elvira Manzano, 20211228000000

Frequent bathroom urgency in patients with ulcerative colitis (UC) could well predict UC severity. Hence, it should be considered a UC-specific patient-reported outcome, said experts at AIBD 2021.

True North: Ozanimod benefits in ulcerative colitis evident in various populations

Roshini Claire Anthony, 20211221180001

A post hoc analysis of the phase III True North study showed that the benefits of ozanimod on clinical remission and response in patients with moderate-to-severe ulcerative colitis (UC) as seen in the global analysis were consistent in the analysis of the North American cohort.

Dietary therapy: Eating the right foods can help modulate IBD

Jairia Dela Cruz, 20211218140000

The gut bacteria are crucial to health and the variable that links inflammatory bowel disease (IBD) to diet. What people eat shapes the composition of bugs that live in the gut, and an imbalance in this composition can promote a range of medical conditions, including IBD. It follows that diet may be involved in the development of IBD, and that diet may be a potential therapy, according to an expert.

IBD therapies do not increase risk of contracting COVID-19 after immunization

Elaine Soliven, 20211218000000

Using biologic/small molecules*, systemic steroids, or other agents** to treat patients with inflammatory bowel disease (IBD) does not increase the rate of SARS-CoV-2 infection at 3 and 6 months post-immunization, according to a study presented at AIBD 2021.

Early vedolizumab treatment uncommon in IBD

Roshini Claire Anthony, 20211217180001

In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.

Wrist strap monitors physiological changes in IBD

Jairia Dela Cruz, 20211217140000

A novel health tracker that is strapped around the wrist can detect changes in the physiology of individuals with inflammatory bowel disease (IBD) in real time, as shown in a study presented at the Advances in Inflammatory Bowel Diseases conference.

Certain IBD meds tied to excess risk of COVID-19 hospitalization

Pearl Toh, 20211216140100

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

NAFLD prevalent in IBD patients

Audrey Abella, 20211216134020

The incidence of nonalcoholic fatty liver disease (NAFLD) is high among individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2021.

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

Pearl Toh, 20211215140100

Treatment with the anti-interleukin (IL)-12/-23 monoclonal antibody ustekinumab yields a high rate of clinical remission in patients with moderate-to-severe Crohn’s disease (CD) in the real-world setting, according to a study presented at AIBD 2021.

Too much processed meat ups mortality risk in IBD patients

Audrey Abella, 20211215035310

Frequent consumption of processed meat was found to be associated with an increased risk of mortality in individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2021. Conversely, this association was not seen with fish and unprocessed meat consumption.